azacitidine has been researched along with hydroxychloroquine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Advani, A; Anwer, F; Carew, JS; Carraway, HE; Espitia, CM; Han, Y; Kelly, KR; Maciejewski, JP; Nawrocki, ST; Phillips, J; Przychodzen, B; Sekeres, MA; Visconte, V | 1 |
| Carew, JS; Espitia, C; Jones, TM; Nawrocki, ST; Wang, W | 1 |
1 review(s) available for azacitidine and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for azacitidine and hydroxychloroquine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Azacitidine; Cell Line, Tumor; Drug Synergism; Humans; Hydroxychloroquine; Mice; Xenograft Model Antitumor Assays | 2019 |
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.
Topics: Animals; Antineoplastic Agents; Autophagy; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Hydroxychloroquine; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lysosomes; Mice | 2019 |